In myositis, 5/6 (83%) patients treated at 4 billion cells per dose with at least three months of follow-up achieved moderate or major responses, as measured by the Total Improvement Score (TIS) in the Ntrust-2 study of
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases,
Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 Cash balance of $216.0 million on September 30, 2026,
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory AffairsCéline Breda
Issued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune
Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For
Equity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc.
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient
Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion
